NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 09 January 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Alex Cale Present for all items
4. Michael Chambers Present for all items
5. Dawn Cooper Present for all items
6. Dr Mark Corbett Present for all items
7. Dr Prithwiraj Das Present for all items
8. Dr Rob Forsyth Present for all items
9. John Hampson Present for all items
10. Iain McGowan Present for all items
11. Ugochi Nwulu Present for all items
12. Stella O’Brien Present for all items
13. Amit Parekh Present for all items
14. Dr Kate Ren Present for all items
15. Professor Andrew Renehan Present for 5.1 to 5.2.2
16. Dr Satish Venkateshan Present for all items

NICE staff (key players) present

Ian Watson, Associate Director Items 1.1 to 4.2.2

Leena Issa, Project Manager Items 1.1 to 4.2.2

Eleanor Donegan, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Samuel Slayen, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 5.1 to 5.2.2

Louise Jafferally, Project Manager Items 5.1 to 5.2.2

Alex Filby, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

George Millington, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Geoff Frampton, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 1.1 to 4.1.3

Neelam Kalita, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 1.1 to 4.1.3

James Mahon, LRiG Items 5.1 to 5.1.2

Nigel Fleeman, LRiG Items 5.1 to 5.1.2

Clinical, Patient & NHS England experts present

Funlayo Odejinmi, Consultant Gynaecologist Obstetrician – **clinical expert** nominated by Theramex (company) Items 1.1 to 4.1.3

Natalie Cooper, Locum Consultant O&G / Honorary clinical lecturer at Queen Mary University London – **clinical expert** nominated by Theramex (company) Items 1.1 to 4.1.3

Peter Clark, **CDF Clinical Lead**, NSHE Items 5.1 to 5.1.2

Dr Donal McLornan, Consultant Haematologist – **clinical expert**, nominated by MPN Voice Items 5.1 to 5.1.2

Professor Tim Somervaille, Professor of Haematological Oncology and Honorary Consultant in Haematology – **clinical expert**, nominated by GSK Items 5.1 to 5.1.2

Andy Tattersall, **Patient expert**, nominated by MPN Voice Items 5.1 to 5.1.2

Charlotte Crowley, Policy and Evidence Manager, Leukaemia Care – **patient expert**, nominated by Leukaemia Care Items 5.1 to 5.1.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Arpit Srivastava, Dr Clare Offer, Elizabeth Thurgar, Iftab Akram, Dr Pedro Saramago Goncalves and Dr Steve Lloyd.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 12 December 2023.

### Appraisal of [linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11131)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Theramex.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11131/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Stephen O’Brien, Michael Chambers and Ugochi Nwulu.
  2. Part 2a – Closed session (company representatives, professional clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11131>

### Appraisal of [momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11064)

* 1. Part 1 – Open session
     1. The chair, Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from GlaxoSmithKline.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11064/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Alex Cale, Mark Corbett and Ugochi Nwulu.
  2. Part 2a – Closed session (company representatives, professional clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11064>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 06 February 2024 and will start promptly at 09:15am.